Big Pharma Sharma
Drug Dealin Ep. 9: Using AI to Find Novel Treatment Options
Big Pharma Sharma
•February 26, 2026•0 min
0
Big Pharma Sharma•Feb 26, 2026
Why It Matters
Understanding how to navigate clinical trial databases and leverage AI democratizes access to cutting‑edge therapies, especially for patients whose standard treatments have failed. This episode is timely as AI models now have larger context windows, making it feasible for individuals to sift through thousands of trial entries and have more informed conversations with their doctors.
Key Takeaways
- •ClinicalTrials.gov offers free, searchable trial data for patients.
- •Filtering Phase 3 trials highlights near‑approval experimental treatments.
- •AI models can parse trial CSVs to recommend relevant studies.
- •Patients can use AI outputs to draft informed doctor communications.
- •Combining public databases and LLMs accelerates treatment option discovery.
Pulse Analysis
The episode opens with hosts Kenny and Shibu arguing that patients must become active architects of their own care, just as homeowners oversee contractors. Using a fictional Parkinson’s patient inspired by a TV scene, they demonstrate how anyone can turn to the publicly available portal ClinicalTrials.gov to locate experimental therapies. By entering a simple disease query, they reveal nearly 4,000 trial listings, underscoring the depth of data that is free to the public and also integral to biotech strategy. This transparency empowers patients to ask informed questions and negotiate better treatment pathways with their physicians.
Next, the hosts download the Phase 3 subset of trials into a CSV file and feed it to a large‑language model such as ChatGPT. The AI scans thousands of entries, extracts eligibility criteria, mechanisms of action, and safety signals, then returns a concise shortlist tailored to a patient whose current medication is failing. By focusing on Phase 3 studies, they prioritize drugs that are closest to regulatory approval, increasing confidence in efficacy and safety. This workflow collapses hours of manual spreadsheet review into minutes, illustrating how AI can democratize biotech intelligence and give patients a data‑driven voice in treatment decisions.
Finally, Kenny shows how the AI‑generated summary can be repurposed into a clear email to a physician, complete with trial identifiers and questions about eligibility. This practical step bridges the gap between raw data and clinical conversation, reducing the intimidation factor for non‑experts. The discussion highlights a broader trend: public trial registries combined with generative AI are reshaping patient advocacy, accelerating drug discovery insights, and lowering barriers for smaller biotech firms. For business leaders, the episode signals that investing in AI‑enhanced data pipelines will become a competitive advantage in personalized medicine and trial recruitment strategies.
Episode Description
How the average person can use clinicaltrials.gov and AI tools to find better care
Show Notes
0
Comments
Want to join the conversation?
Loading comments...